RHYTHM PHARMACEUTICALS

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

03 Jun 2024 16:02:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

03 Jun 2024 08:02:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

22 May 2024 04:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

09 May 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

29 Apr 2024 18:30:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

24 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

25 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

06 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22 Feb 2024 07:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

07 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

31 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

12 Jan 2024 16:01:00 By Nasdaq GlobeNewswire